Leadership

Oncopeptides’ senior management team consists of the CEO, CFO, Chief Medical Officer, Chief Operating Officer, Director of IR & Communications and Head of Human Resources.

Together, they represent a mix of scientific, financial, operational, and organizational expertise.

This diversity of skills ensures focused execution of our strategy, responsible governance, and continued value creation for patients, employees, and shareholders.

Sofia Heigis, MSc

Chief Executive Officer, CEO

Born:

1980

Holdings:

263,499 shares, 3,474,093 share awards and 134,180 options

Other current positions:

Sofia Heigis, MSc

Chief Executive Officer, CEO

Sofia was appointed Chief Executive Officer in August 2023.

Sofia joined Oncopeptides in August 2020 as Senior Vice President and Global Head Medical Affairs. She was appointed Chief Commercial Officer and Managing Director Germany in 2022. Sofia was engaged in the preparedness and launch of Pepaxto in the US, and has led the preparations of the commercialization of Pepaxti in Europe. She has been a member of the Leadership Team since November 2021.

Sofia brings broad experience from leading international roles in Medical Affairs, Regulatory Affairs, Market Ethics, Pharmacovigilance, Real World Evidence as well as several Marketing and Sales roles at Astra Zeneca, and has been engaged in both global and local product launches.

Sofia holds a Master of Pharmacology from the University of Gothenburg, including a Master Thesis in Pharmacology from Bond University. She has an Executive Master in Strategy, and is a member of the business network for female leaders, Ruter Dam.

Eva Nordström, MSc Pharm

Chief Operating Officer (COO) and Deputy Managing Director

Born:

1970

Holdings:

420,696 shares, 366,280 share awards and 252,312 options

Other current positions:

Board member of Oxcia AB, Alternate Director of Utilica AB

Eva Nordström, MSc Pharm

Chief Operating Officer (COO) and Deputy Managing Director

Eva Nordström was appointed as Head of Clinical Development in 2012, Chief Operating Officer 2020 and Deputy Managing Director 2021. Eva is responsible for strategic and operational deliveries in Biometrics, CMC, Clinical Operations, Global Drug Supply and Preclinical Operations.

Previous positions Eva has held include Global Product Director and Vice President roles at Pharmacia and AstraZeneca based both in Sweden and the USA. She has led international cross-functional teams through all phases of drug development, including phase III and product launches. Eva has been responsible for individual project strategies including their implementation as well as disease area strategies, portfolio management and in-licensing.

Eva holds an MSc Pharm from Uppsala University and an Executive MBA from Stockholm School of Economics.

Henrik Bergentoft, MSc

Chief Financial Officer (CFO)

Born:

1974

Holdings:

42,774 shares and 205,106 share awards

Other current positions:

Henrik Bergentoft, MSc

Chief Financial Officer (CFO)

Henrik was appointed CFO in 2023 and is responsible for Finance, Legal, IT and administration.

Henrik brings broad experience from several CFO-positions in listed companies; RaySearch Laboratories, C-RAD, MSAB, Nordkom, Aerocrine and Contextvision. He started his career as auditor with Andersen/Deloitte.

Henrik has a Master of science in Business Administration from the University of Uppsala.

David Augustsson, MSc

Director of IR and Communications

Born:

1984

Holdings:

41,583 shares and 115,630 share awards

Other current positions:

David Augustsson, MSc

Director of IR and Communications

David Augustsson joined Oncopeptides in 2023 as Head of the company’s investor relations, communications and corporate brand.

David has a broad experience from leading communication roles in international and listed companies. Between 2016 and 2023, he worked for global financial services company Nasdaq, where he led the communications teams for the company’s European operations as well as its global technology business. He has also worked as a consultant at a number of agencies, including WeberShandwick and Hill+Knowlton, where he primarily has worked with financial communications and issues management. David is also a regular guest lecturer within strategic communication and issues management at Berghs School of Communication in Stockholm.

David holds a Master’s degree in International Economics and Management from Uppsala University and Wirtschaftsuniversität Vienna.

Lotta Larsson

Head of Human Resources

Born:

1977

Holdings:

39,560 share awards

Other current positions:

Lotta Larsson

Head of Human Resources

Lotta joined Oncopeptides in September 2024 as Head of Human Resources.

Lotta brings almost 20 years of HR leadership experience from the life sciences sector, with deep expertise in establishing and managing global HR functions in fast-growing, international environments. Her focus has been on aligning HR strategies with business objectives to drive long-term growth and efficiency and delivering high-quality HR support across the full range of HR activities. Prior to joining Oncopeptides, Lotta held senior HR roles at medtech company RaySearch Laboratories AB and biotech company BioLamina AB.

Lotta holds a Bachelor of Applied Science (B.A.Sc.) in Dietetics and Clinical Nutrition Services and a Bachelor of Applied Science (B.A.Sc.) in Health Sciences Health Promotion from Deakin University, Australia.

Stefan Norin, MD, PhD

Chief Medical Officer (CMO)

Born:

1972

Holdings:

21,799 shares, 192,290 share awards and 16,242 options

Other current positions:

Stefan Norin, MD, PhD

Chief Medical Officer (CMO)

Stefan was appointed as Chief Medical Officer in September 2023.

Stefan joined Oncopeptides in March 2019, as Clinical Study Physician, appointed Global Clinical Lead in 2020, Head of Clinical Development in 2022 and Head of Clinical Science in 2023.

In his role, he is responsible for Research & Development and Pharmacovigilance.

Stefan has a background as a specialist in Internal Medicine and Hematology and has 20 years of clinical experience. He has a PhD from Karolinska Institute.

Previous roles include Associate Director, Clinical R&D at Medivir AB and Head of Lymphoma Division, Department of Hematology at Karolinska University Hospital.

Board of Directors

After the general meeting, the board of directors is the Company’s highest decision-making body.

The board of directors are responsible for the organization and management of the company’s affairs, for example by establishing targets and strategies and continuously assess the company’s financial position and evaluate the operational management.

Per Wold-Olsen

Chairman

Born:

1947

Holdings:

1,915,935 shares, 168,554 share awards and 17,226 options

Other current positions:

Board member of Forefront Capital Partners.

Board committees:

Chairman of the Remuneration Committee and member of the Audit and Nomination Committee

Per Wold-Olsen

Chairman

Per Wold-Olsen was appointed as Chairman of the Board in 2018.

Per has an extensive experience in the pharmaceutical industry and has held many different positions within Merck & Co Inc. He served on Merck’s management team between 1994-2006. Since 2006 he has served on several boards in the life science sector including Lundbeck, Pharmaset, Royal Dutch Numico, Amarin and GN Store Nord.

Per holds a MBA in Economics and Administration from Handelshøyskolen BI and a MBA in Management and Marketing from the University of Wisconsin.

Independent in relation to the Company and its management and in relation to major shareholders.

Brian Stuglik, B.Pharm

Board member

Born:

1959

Holdings:

216,057 share awards and 6,893 options

Other current positions:

CEO of Verastem Inc., Board Member of Puma Biotechnology; Founder of Proventus Health Solutions LLC. Member of the American Society of Clinical Oncology, the American Association for Cancer Research and the International Association for Lung Cancer Studies.

Board committees:

Member of the Remuneration Committee

Brian Stuglik, B.Pharm

Board member

Brian Stuglik was appointed to the Board of Oncopeptides 2018.

Brian has a long and broad experience from the pharmaceutical industry. He has spent 30 years in different positions within Eli Lilly, including American as well as global roles and responsibilities. Over the past 25 years, his work has been focused on product strategy and commercialization for oncology products.

Brian holds a Bachelor of Pharmacy from Purdue University, US.

Independent in relation to the Company and its management and in relation to major shareholders.

Christine Rankin

Board member

Born:

1964

Holdings:

43,893 shares and 58,608 share awards

Other current positions:

Board member and Head of the audit committee of Starbreeze AB, Board member and Head of the audit committee of Bonesupport AB, Board Member and Head of the audit committee of Orexo AB, Board member and Head of the audit committee of 4C Group AB, Board member and Head of the audit committee of Coinshares PLC.

Board committees:

Chairman of the Audit Committee

Christine Rankin

Board member

Christine Rankin was appointed to the board of Oncopeptides in 2025.

Christine has since 2017 held external board positions in listed companies and has extensive experience of leading positions in public companies, as CFO and positions directly under the CFO. Christine started her professional career at PwC as a public accountant, specialising in listed companies, where she was partner between 2001 and 2014.

Christine holds a Bachelor of Business Administration and Economics from Stockholm University.

Independent in relation to the Company and its management and in relation to major shareholders.

Per Samuelsson, MSc

Board member

Born:

1961

Holdings:

Other current positions:

Board Member of Ariceum Therapeutics GmbH, Cantando AB, Cantando Holding AB, HealthCap AB, HealthCap Annex Fund I-II GP AB, Pretzel Therapeutics, Inc., Skipjack AB.

Board committees:

Member of the Audit Committee and the Remuneration Committee

Per Samuelsson, MSc

Board member

Per Samuelsson was appointed to the board of Oncopeptides in 2012.

Per is a partner at HealthCap, a life sciences venture capital business.

Per has 25 years of experience from investing venture capital in the life science sector. Before that, Per gained over 15 years of investment banking experience, mainly with Aros Securities based in Sweden. At Aros Securities he held several roles including being a Director in the corporate finance department where he specialized in merger transactions, initial public offerings and equity incentive programs. Per also held the role of Head of Research at Aros Securities.

Per holds an MSc in Engineering from the Institute of Technology in Linköping, Sweden.

Independent in relation to the Company and its senior management, but not in relation to major shareholders. Partner in HealthCap and holder of directorships in several companies within the HealthCap Group.